Relmada Therapeutics (RLMD) Stock Analysis

What Relmada Therapeutics does

Relmada Therapeutics, Inc. operates as a clinical-stage biotechnology company in the United States. The company focuses on the development of NDV-01, a controlled-release intravesical formulation of gemcitabine and docetaxel, which is in Phase 2 clinical trial for patients with aggressive forms of non-muscle invasive bladder cancer; and Sepranolone, a neurosteroid epimer of allopregnanolone, which is Phase 2b-ready for the potential treatment of prader-willi syndrome, tourette syndrome, excessive tremor, and other diseases related to excessive GABAergic activity. The company has an agreement with Asarina Pharma AB and Trigone. Relmada Therapeutics, Inc. was founded in 2004 and is headquartered in Coral Gables, Florida.

Key metrics

ETFs linked to RLMD

Broad-market and Healthcare sector ETFs an investor holding Relmada Therapeutics is often also exposed to. Open an ETF page to see its actual top holdings.

PortView Portfolio Insights

PortView analyzes how RLMD fits your actual portfolio — position weight, portfolio concentration, unrealized gain/loss, contribution to return, sector exposure, indirect exposure through the ETFs you hold, and correlation with your other holdings. Connect a portfolio to see your personalized figures; PortView never shows another user's private holdings.

Similar companies

Frequently asked questions

What is the ticker symbol for Relmada Therapeutics?

Relmada Therapeutics trades under the ticker RLMD on NASDAQ.

Which exchange is RLMD listed on?

RLMD is listed on NASDAQ.

What sector does Relmada Therapeutics operate in?

Relmada Therapeutics is classified in the Healthcare sector (Biotechnology industry).

How can PortView help analyze RLMD in a portfolio?

PortView shows RLMD's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.